Content
All Posts > Content under Healthcare
Vertex Pharmaceuticals Reports Positive Results From Two Trials
Article By:
KKD Healthcare Analytics
Read
Wednesday, March 29, 2017 1:02 PM EDT
Vertex Pharmaceuticals stock jumped over 22 percent in its current trading session as it also created a new 52 weeks high of $111.88.
In this article: VRTX
Pernix Therapeutics Holdings, Inc. Shares Take A Dive On Poor Earnings Results
Article By:
TickerTV
Read
Wednesday, March 29, 2017 11:00 AM EDT
PTX opened trading yesterday at $4.22 which was up from the previous day’s trading close of $4.17. Shares closed trading yesterday at $4.06 and spiked down aftermarket to $3.50, equivalent to a 14% decrease from the closing price.
In this article: PTX
Global Stocks, S&P Futures Little Changed On Brexit Day
Article By:
Tyler Durden
Read
Wednesday, March 29, 2017 6:50 AM EDT
Brexit day has finally arrived, and despite this major "risk event", European and Asian stocks are trading mixed, while S&P futures are just fractionally lower as a bounce on optimism over the American economy appears to have fizzled.
Will Healthcare And Biotech Resume Market Leadership?
Article By:
Justin Smyth
Read
Wednesday, March 29, 2017 5:37 AM EDT
Biotech ETFs XBI and IBB are outperforming so far this year. It’s not too surprising if you use Stage Analysis since we know that bear markets are authors of bull markets, and biotech was one of the worst performing sectors of 2016.
Pulse Biosciences - Screaming Short
Article By:
Jim Van Meerten
Read
Tuesday, March 28, 2017 8:47 PM EDT
Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling.
In this article: PLSE
Regeneron And Sanofi Win FDA Approval For Their Expected Mega Blockbuster Eczema Drug Dupixent
Article By:
Lorimer Wilson
Read
Tuesday, March 28, 2017 2:20 PM EDT
The FDA has approved the eczema drug dupilumab (to be branded as Dupixent) from Regeneron Pharmaceuticals and Sanofi which is likely to become a mega-blockbuster franchise worth upwards of $5 billion a year for these two partners.
Verastem Creates New 52 Weeks High
Article By:
KKD Healthcare Analytics
Read
Tuesday, March 28, 2017 1:05 PM EDT
Verastem stock has shown strong performance as it grew over 44 percent in the past 12 months.
In this article: VSTM
Investors Remain Cautious As Trump Meets Unexpected
Article By:
Sabrient Systems
Read
Tuesday, March 28, 2017 11:58 AM EDT
The SPY closed Monday at 233.62 after recovering from what started out looking like “the next leg down.” March has shaped up as a month for an orderly correction to the 4-month post-election rally.
FDA OKs Tesaro’s "Niraparib" For Ovarian Cancer - Major Setback For Myriad Genetics Inc
Article By:
Lorimer Wilson
Read
Tuesday, March 28, 2017 11:10 AM EDT
Tesaro, Inc. has been given a broad approval by the FDA for the use of its PARP drug niraparib, which will now be marketed as Zejula as a maintenance therapy for recurrent ovarian cancer which represents a major setback for Myriad Genetics, Inc.
Hospital Stocks Soar Upon The Death Of TrumpCare
Article By:
Zacks Investment Research
Read
Tuesday, March 28, 2017 10:12 AM EDT
While the Republican’s unsuccessful attempt to repeal and replace the Affordable Care Act was a disaster for the GOP, it was great news for hospital stocks like HCA Holdings and Universal Health Service Inc.
Market Briefing For Tuesday, March 28
Article By:
Gene Inger
Read
Tuesday, March 28, 2017 7:47 AM EDT
Tax relief is capable of assisting the market. However, there's a lot riding on the technical efforts to rebound, as are underway short-term.